ViroCell arrow logo-102-153-255.png
 

Powered by science Driven by passion

 

The Leadership Team


JOHN W. HADDEN II

Chief Executive Officer

Co-Founder

John W. Hadden II is Chief Executive Officer and co-founder of ViroCell Biologics. A successful serial entrepreneur, John’s passion for science and medicine and business acumen have enabled him to meet the challenges of the journey from laboratory to clinic to marketing authorization with a range of life science companies.

In addition to his board membership with ViroCell Biologics, John has substantial board and governance experience with for-profit companies, as well as non-profit organizations.  

John has extensive experience shaping and executing strategy, building strong partnerships, managing transformational change and leading genuinely diverse organizations.  

 

FARZIN FARZANEH, PhD

Chief Scientific Officer

Co-Founder

Farzin Farzaneh, PhD, FRCPath, FRSB, is Chief Scientific Officer of ViroCell Biologics and serves as a member of the Board of Directors. He is also Chair of Molecular Medicine at King’s College London and Trans-campus Professor of Molecular Medicine at Technical University of Dresden, Germany.

He established the Rayne Cell and Gene Therapy Suite (RCTS) for the GMP manufacture of Investigational Medicinal Products (IMP) and Advanced Therapy Medicinal Products (ATMP) at King’s in 2001. This facility has produced the largest number of viral vectors for gene therapy based clinical studies in Europe. He is also Member of the MHRA Commission on Human Medicines: Clinical Trials, Biologicals & Vaccines (CTBV) Expert Advisory Group.

 

BRIAN COLLINS

Chief Financial Officer

Brian Collins is Chief Financial Officer of ViroCell Biologics. He brings over thirty years of financial and operations leadership experience from working at large corporations, private equity and not-for-profits in the UK, Switzerland, and the US. 

Most recently, Brian was CFO at the Cell and Gene Therapy Catapult, an independent innovation and technology organization committed to the advancement of cell and gene therapies. He oversaw the Corporate Services team which included Finance, HR, IT, Procurement as well as the Operational Excellence program.

 

TONI TREVETT, FCIPD

Chief People Officer

Toni Trevett, FCIPD, is Chief People Officer at ViroCell Biologics. She has spent many years working and consulting in people management and has held leadership roles in large corporations in the UK, including as an HR Director within the BAA Plc group. 

Toni has worked in organizations in various industries including Talbot Underwriting Ltd., Lewis Silkin LLB, AAT, BAT Plc, Stihl, and Featurespace, among others.


RITA TENDEIRO REGO, PhD, MRSB, UK QP

SVP, Quality

 

JASON TANG

VP, Legal


CLARE MILLAR

VP, Programme Delivery

 

TRACI KYES

VP, Business Development (U.S.)


JAMES AINSWORTH

VP, Information Systems


MAKIS SIGALAS, PhD

Senior Director, Business Development (Europe)


CARLO SCALA, PhD

Director, Process Development & Innovation

 

NICHOLAS OSTROUT, PhD

VP, Corporate Development and Strategy


GAIK SUI KEE, PhD, CEng

Director, Manufacturing 


DAVID DARLING, PhD

Senior Principal Scientist, Innovation

 

We have a very experienced group of people. There’s a high degree of collaboration and when we see this teamwork at work, we call it Team Intelligence™.
— JOHN W. HADDEN II, CHIEF EXECUTIVE OFFICER